info@nano-mab.com

About info nano-mab

This author has not yet filled in any details.
So far info nano-mab has created 6 blog entries.

NanoMab receives MHRA approval to commence a Phase 2 Clinical Study to investigate PD-L1 expression using its NM-01 product as a tool for non-invasive in vivo imaging.

2020-11-05T02:54:55+00:00

London, November 4th, 2020:  NanoMab Technology Limited, a privately held biopharmaceutical company focussing on cancer precision therapies, today announced that it had received CTA Acceptance from the Medicines Healthcare products Regulatory Agency (MHRA) to carry out a Phase II clinical Study for its NM-01 product. The study (“PELICAN”) will investigate the assessment of programmed death [...]

NanoMab receives MHRA approval to commence a Phase 2 Clinical Study to investigate PD-L1 expression using its NM-01 product as a tool for non-invasive in vivo imaging.2020-11-05T02:54:55+00:00

NanoMab and OncoBeta outline the pathway to a Strategic Alliance and Supply Agreement, focused on the secure supply of Rhenium-188 for NanoMab’s range of Therapeutic Radiopharmaceuticals

2020-10-27T01:58:31+00:00

London, October 27th, 2020: NanoMab Technology Limited, a privately held biopharmaceutical company focussing on precision cancer therapies, today announced that it had signed Heads of Terms with OncoBeta® GmbH, a supplier of Tungsten-188/ Rhenium-188 generators for the production of high-energy beta emitting Rhenium-188, as well as a commercial stage medical device company specialized in innovative [...]

NanoMab and OncoBeta outline the pathway to a Strategic Alliance and Supply Agreement, focused on the secure supply of Rhenium-188 for NanoMab’s range of Therapeutic Radiopharmaceuticals2020-10-27T01:58:31+00:00

NanoMab announces the commencement of the NM-01 mechanistic study (SPECT/CT radiotracer) for non-small cell lung cancer patients.

2020-10-09T08:28:07+00:00

London, October 8th, 2020:  NanoMab Technology Limited, a privately held biopharmaceutical company focussing on cancer precision therapies, today announced that in collaboration with King’s College London and Guys & St Thomas’ Hospitals, it has commenced a mechanistic study to noninvasively assess PD-L1 expression using 99mTc-NM-01 as a SPECT/CT radiotracer. Professor Gary Cook, Professor of PET [...]

NanoMab announces the commencement of the NM-01 mechanistic study (SPECT/CT radiotracer) for non-small cell lung cancer patients.2020-10-09T08:28:07+00:00

NanoMab Submits a request to the MHRA to commence a Phase 2 Clinical Study to investigate PD-L1 expression using its NM-01 product as a tool for non-invasive in vivo imaging

2020-09-10T06:52:58+00:00

London, September 9th, 2020:  NanoMab Technology Limited, a privately held biopharmaceutical company focussing on cancer precision therapies, today announced that it had submitted a request to the MHRA for authorisation for a Phase II Clinical Study Protocol for its NM-01 product. The study will investigate the assessment of programmed death ligand 1 (PD-L1) expression using [...]

NanoMab Submits a request to the MHRA to commence a Phase 2 Clinical Study to investigate PD-L1 expression using its NM-01 product as a tool for non-invasive in vivo imaging2020-09-10T06:52:58+00:00